Efficacy
death
REMISSION
Among 37 patients evaluable for a response, mORR was observed in 17 (39%), of which CR and marrow CR (mCR) was achieved by 3 (7%) and 14 (32%) patients, respectively (Table Efficacy among patients treated with venetoclax and azacitidine
Abbreviations: CR, complete remission; HI, hematologic improvement; mCR, marrow CR; mORR, Modified overall response rate; NE, not evaluable; PR, partial remission.Patients who achieved any component of (CR + PR + mCR + HI).HI = HI‐E + HI‐P + HI‐N; HI‐E, Transfusion dependent on packed red blood cells or whole blood 8 weeks prior to cycle 1 day 1 (C1D1) or hemoglobin level < 11 g/dl; HI‐P, Transfusion dependent on platelet 8 weeks prior to C1D1 or platelet counts <100 × 10The post‐baseline transfusion independence rate is defined as a period of at least 56 days with no transfusion during the evaluation period. The evaluation period for transfusion independence is from the date of the first dose of the study drug to the last dose of the study drug +30 days or 1 day before the date of progressive disease from disease response (2006 IWG) electronic clinical report form, death, or the initiation of post‐treatment therapy whichever is earliest.(A) Duration of response (DoR). (B) Overall survival (OS) in patients treated with venetoclax (Ven) and azacitidine (Aza). [Color figure can be viewed at Patients with 